Streetbeat News

LRMR

Larimar Therapeutics, Inc.

https://www.larimartx.com

Industry

Biotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

Open

3.32

Mkt cap

213M

Volume

526K

High

3.39

P/E Ratio

-2.90

52-wk high

13.68

Low

3.21

Div yield

N/A

52-wk low

3.01

Larimar Therapeutics reported positive initial data from a phase 2 study using nomlabofusp for Friedreich's Ataxia, showing increased tissue FXN protein levels. The Friedreich's Ataxia market is projected to grow significantly by 2030, with more data expected in 2025.

Portfolio Pulse from

January 03, 2025 | 11:00 pm

Larimar Therapeutics announced positive initial data from its ongoing long-term open-label extension study for nomlabofusp, a treatment for Friedreich's Ataxia. The study involves daily subcutaneous injections and shows promising results.

Portfolio Pulse from

December 16, 2024 | 12:15 pm

HC Wainwright & Co. analyst Edward White has reiterated a Buy rating for Larimar Therapeutics (NASDAQ:LRMR) and maintained a price target of $15.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 9:42 am

Larimar Therapeutics shares rose following the announcement of better-than-expected Q3 EPS results.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 3:34 pm

Larimar Therapeutics reported a Q3 2024 GAAP EPS of $(0.24), beating the analyst estimate of $(0.39). The company has $203.7M in cash and equivalents.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 11:21 am

Oppenheimer has initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Outperform rating and a $26 price target, citing the potential of its lead drug, Nomlabofusp, to transform treatment for Friedreich’s ataxia. The drug targets frataxin deficiency, a key factor in the disease. Larimar plans to expand into pediatric populations and pursue accelerated FDA approval. The company aims for a U.S. launch in 2027 and a European launch in 2028, with projected global revenues of $1.2 billion by 2030. The stock is currently up 2.56% at $7.61.

Portfolio Pulse from Vandana Singh

October 16, 2024 | 6:59 pm

Larimar Therapeutics shares rose after Oppenheimer initiated coverage with an Outperform rating and a $26 price target.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 4:23 pm

Oppenheimer has initiated coverage on Larimar Therapeutics with an Outperform rating and set a price target of $26.

Portfolio Pulse from Benzinga Newsdesk

October 16, 2024 | 9:09 am

Larimar Therapeutics shares rose after Wedbush initiated coverage with an Outperform rating and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 3:01 pm

Wedbush analyst Laura Chico has initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Outperform rating and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

October 03, 2024 | 1:49 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.